KINSALE CAPITAL GROUP, INC. (KNSL): what the price assumes

In the published model solve dated 2026-Q2, anchored at $378.64, KINSALE CAPITAL GROUP, INC. (KNSL) is priced for 27.0% return on equity. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-06-29.

Generated: 2026-07-29 · Exported: 2026-08-01 · Source: https://boothcheck.com/report/KNSL

Headline

FieldValue
TickerKNSL
CompanyKINSALE CAPITAL GROUP, INC.
Current price$378.64/sh

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basisfinancials
Elite ROE must persist for11.2y before normalizing (held at the 25% elite tier)
Perpetuity-equivalent ROE27.0%
Return on equity now25.7%
ROE gap+1.3pp
Price-to-book4.44x

Solve inputs: computed at a 9.2% cost of equity; ROE searched up to the 25% ROE ceiling; each 1pp moves the implied horizon ~0.8 years.

How unusual the bet is: within-range

ReferenceValue
vs own history+1.43σ
cohort percentile (of 88 peers)89
sustained it ~10 years at this level44%
implied end-window share0%

Valuation X-Ray

The price is supported by earnings-power and relative-multiple and growth-DCF value, while asset-based lands below the price. A value/asset-supported name, not a pure growth bet.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset1.53x3expensive
Earnings1.03x2expensive
Relative0.54x3justifies
Growth1.03x1expensive

Families that justify the price: Earnings, Relative, Growth Families that call it expensive: Asset

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 9.1%); the inversion above states its own rate.

Per-Model Detail (n=9)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowth——no—
Bank Fair Value (P/TBV)—$437.350.87xyesTBVPS $85.33 × 5.13x (ROE (TTM) 26.8% / CoE 9.3%, g=5.0% (sustainable: 65% retention × ROE, 5% cap; not the terminal-growth assumption))
Relative ValuationRelative$339.301.12xyesP/E 12.67x (blended: static sector reference 11x + trailing (TTM) 17x), scenarios: 10.4x / 12.7x / 14.9x (bear / base = reference held flat / bull), EV/EBITDA 10x
Simple DDMGrowth——no—
Two-Stage DDMGrowth——no—
Simple Excess ReturnAsset$247.071.53xyesBV/sh $85.33, ROE (TTM) 26.8%, ke 9.3%
Two-Stage Excess ReturnAsset$426.170.89xyes5yr excess ROE then converge to ke=9.3%
Discounted Future Market CapGrowth$368.201.03xyesRev $1.9B, growth 17% (input: historical growth; tapered), Terminal P/S: 3.7x / 4.6x / 5.4x (bear / base = today's held flat / bull, cap 12x)
Peter Lynch Fair ValueRelative$707.250.54xyesEPS $22.70, growth 31% (input: historical EPS growth), PEG=0.53 (Undervalued)
Margin TrajectoryGrowth——no—
Earnings Power ValueEarnings——no—
Residual IncomeAsset——no—
Graham NumberAsset$208.761.81xyes√(22.5 × EPS $22.70 × BVPS $85.33) — Graham's conservative floor
EV/EBITDA RelativeRelative——no—
FCF YieldEarnings——no—
SBC-Adj FCF YieldEarnings——no—
Ben Graham FormulaEarnings$732.450.52xyesEPS $22.70 × (8.5 + 2×15.0%) × (4.4 / 5.3%)
ROIC-Justified P/BAsset——no—
P/Sales SectorRelative——no—
PEG Fair ValueRelative$851.250.44xyesEPS $22.70 × (PEG 1.5 × growth 25.0% (input: historical EPS growth)) → PE 37.5x
Earnings YieldEarnings$245.411.54xyesEPS $22.70 / required return 9.3% (Rf 4.3% + ERP 5.0%)
Funds From Operations MultipleRelative——no—
Clinical Phase NPVGrowth——no—
MertonAsset——no—
V5 Mechanical———no—

Solvency

FieldValue
Share count CAGR (dilution)0.0%

Deposit/float-funded balance sheet: debt is funding, not corporate leverage, and GAAP operating cash flow follows loan flows. Net-debt, interest-coverage, and cash-burn lenses do not apply. The solvency frame for a financial is regulatory capital and payout capacity (CET1, stress buffer, dividends plus buybacks against earnings).

Bullet Takeaways

Bull Case

Start with where the price lands against the methods, because for Kinsale that map is unusually friendly to a holder. Most of this report's names trade above what the standard methods support; Kinsale does not. The asset-value lens, the earnings-power lens, the peer-multiple lens, and the forward-growth lens all land at or below today's price, which means the quote is not floating on a single optimistic frame. The peer-multiple lens in particular reads Kinsale as inexpensive relative to its specialty-insurance cohort, despite the stock carrying one of the highest returns on equity in the group. When every family of method supports the price and one of them calls it cheap, the spread itself is the bull argument: the market is not paying a premium that only a heroic assumption can justify.

What earns that support is the underwriting. Kinsale wrote a 77.4% combined ratio in Q1 2026, an improvement of 4.7 points year over year, helped by light catastrophe losses and disciplined risk selection. A combined ratio in the high 70s is exceptional in property-casualty insurance, where many carriers operate near or above 100% and depend on investment income to turn a profit; Kinsale is profitable on the insurance itself before a dollar of float is invested. That underwriting margin is why the company earns the returns it does. Operating earnings reached $5.11 per share in Q1 2026, up 37.7% year over year, on an annualized operating return on equity of 24%. The reverse lens on the price puts the long-run number a bit lower, around the low-20s on equity, which is the rare territory only the strongest financials reach.

The structural advantage behind those numbers is the excess-and-surplus niche itself. Kinsale writes the hard-to-place risks that admitted carriers decline, where pricing is freer, competition is thinner, and the company controls its own technology and claims handling rather than renting it. That control is what lets it move fast on price and keep its expense ratio low. The capital story reinforces the bull: the share count is essentially flat to slightly higher rather than ballooning, book value compounds at the elite return, and the business funds its own growth internally. An investor buying Kinsale is buying a compounder whose math works at today's price on the methods, not in spite of them.

Bear Case

The bear case for Kinsale begins with a tension that the headline returns hide: the engine that justifies a 3.6x book multiple is a growth engine, and the growth just stalled. Gross written premium fell 0.5% in Q1 2026, the first time the company's signature double-digit top-line expansion has gone flat, as competition crowded into large commercial property and pricing softened. A specialty insurer paying out elite returns is only worth a steep premium to book if it can keep redeploying capital at those returns into a growing book of business. When the premium base stops growing, the compounding machine that the multiple pays for slows with it, and the market noticed: one analyst moved to an Underperform rating in early 2026 on the view that growth could settle into the low single digits, materially below where consensus had it.

That qualitative concern has a precise arithmetic form. At today's price, the stock is paying about 3.6 times book value, and the embedded assumption is that Kinsale sustains a return on equity in the low-20s for roughly two decades before normalizing toward its cost of equity near 9%. The company currently earns about 25.7% on a trailing basis, so there is genuine headroom; the question is durability, not current quality. The return Kinsale must sustain to justify the price sits above the level its own panel of strong financials typically holds over a long horizon, which is the engine flagging that the bet runs to the upper end of plausible. If that return mean-reverts faster, because the E&S pricing cycle turns or competition compresses the underwriting margin, the price-to-book the stock supports compresses with it, and a multiple that high has a long way to fall.

The cyclical and structural risks behind that requirement are real. Excess-and-surplus pricing is famously cyclical; the favorable conditions of recent years are precisely the kind that draw in capacity and erode the pricing power Kinsale depends on, and the flat premium line is an early read on that pressure. The combined ratio in the high 70s, while a strength today, is also near the top of what is achievable, which means the margin has more room to deteriorate than to improve. And catastrophe exposure is inherent to property underwriting: a light-catastrophe quarter flattered the Q1 combined ratio, and a heavy one would do the reverse. None of these is a solvency concern; for an insurer the frame is capital adequacy and payout capacity, and Kinsale is well capitalized. The bear is not that Kinsale breaks. It is that a high-quality compounder priced for the compounding to persist has, for the first time, shown the top line going flat.

Valuation

Kinsale is read the way an insurer should be read: on price-to-book and return on equity, with the cash-flow and operating-multiple lenses set aside because they misfit a float-funded balance sheet. The company trades at about 3.6 times book value, the very top of its specialty-insurance peer group, and the disciplined translation of that multiple is a return-durability question rather than a fair-value number.

What is unusual, and worth stating plainly, is how broadly the methods support the price. Every family of method reaches it: the asset-based lens anchored on book value and the elite return, the earnings-power lens, the forward-growth lens, and the peer-multiple lens, which actually reads Kinsale as cheap against its cohort. That is the opposite of a stock floating on one optimistic frame. The reverse lens reframes the same picture as a duration bet: the price assumes Kinsale keeps earning a return on equity in the low-20s for roughly two decades before fading toward its cost of equity near 9%. Against a current trailing return of about 25.7% and an annualized Q1 2026 operating return near 24%, there is real headroom, but the required return still sits above what the broader panel of strong financials typically sustains over that long a horizon. The price is paying close to the high end of what even a generous durability assumption supports, which is why the methods cluster around the price rather than well below it.

The peer comparison sharpens the picture without needing a target. Kinsale's combined ratio of 77.4% is well inside what most property-casualty carriers achieve, and that underwriting margin is the source of the returns the multiple pays for; the multiple is high precisely because the underwriting is rare. The street's mean analyst target sits at roughly $432 with a Hold consensus, which credits more durability of the elite return than the backward-looking methods will, and the gap between that target and the static lenses is exactly the growth-and-durability premium the cycle now puts in question. On solvency, the right frame for an insurer is capital adequacy and payout capacity, not leverage or cash burn; on that frame Kinsale is well capitalized, funds its own growth, and returns capital steadily. The risk in this name is not the balance sheet. It is whether the return that the price pays a top-of-group multiple for keeps compounding now that the top line has gone flat.

Catalysts

The catalyst that matters most for Kinsale is the premium-growth trajectory, because it is the variable the multiple is most sensitive to. Gross written premium slipped 0.5% in Q1 2026, with the pressure concentrated in large commercial property where competition has intensified, while net written premium still grew 5.6% as management leaned into lines that carry less reinsurance. The next several prints are the test of whether this is a temporary air pocket in one division or the start of a slower-growth regime; the bull and bear cases hinge on that distinction, and so does the multiple.

Analyst sentiment has already moved on the question. The consensus rating is Hold, and in early 2026 one firm downgraded the stock to Underperform on the expectation that growth could run in the low single digits, well below where the street had been modeling it; price targets across property-casualty insurers were trimmed as analysts reset growth assumptions for a softer pricing cycle. The mean target near $432 still sits above the current price, so the disagreement is about durability of returns rather than imminent deterioration.

Underneath the growth debate, the underwriting result is the offsetting catalyst. The combined ratio improved 4.7 points to 77.4% and operating earnings per share rose 37.7% in Q1 2026, which shows that even with the top line flat, the profitability of each premium dollar is still expanding. Catastrophe experience will swing the combined ratio quarter to quarter, and a heavy season would compress the margin that currently flatters the result, so the path of both premium growth and catastrophe losses through the rest of 2026 is what to watch.

Peer Cohorts (Per Segment, With Filing Citations)

Specialty insurance (E&S) (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

Sources

Q1 2026 earnings release · BMO Capital research note, Feb 2026 · analyst consensus, May 2026 · analyst commentary, 2026

View the full interactive KNSL report on boothcheck